ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BSTC BioSpecifics Technologies Corp

88.53
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioSpecifics Technologies Corp NASDAQ:BSTC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 88.53 90.00 90.00 0 01:00:00

BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences

30/08/2018 1:01pm

PR Newswire (US)


BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more BioSpecifics Technologies Charts.

LYNBROOK, N.Y., Aug. 30, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences in September.

  • H.C. Wainwright 20th Annual Global Investment Conference at 4:15 p.m. on Thursday, September 6, 2018 in New York, NY.
  • 25th Annual BioCentury NewsMakers in The Biotech Industry Conference at 2:00 p.m. ET on Friday, September 7, 2018 in New York, NY.

A live audio webcast of each presentation can be accessed under the "Events and Presentation" tab in the Investors section of the Company's website at www.biospecifics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Canada, Europe and Australia. The CCH research and development pipeline includes several additional promising indications, including Phase 3 clinical trials for the treatment of cellulite with top-line data expected in the fourth quarter of 2018. BioSpecifics is managing the development of CCH for the treatment of uterine fibroids the Phase 1 clinical trial is now fully enrolled with top-line data expected in the fourth quarter of 2018. For more information, please visit www.biospecifics.com.

Cision View original content:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-two-upcoming-september-conferences-300703814.html

SOURCE BioSpecifics Technologies Corp.

Copyright 2018 PR Newswire

1 Year BioSpecifics Technologies Chart

1 Year BioSpecifics Technologies Chart

1 Month BioSpecifics Technologies Chart

1 Month BioSpecifics Technologies Chart

Your Recent History

Delayed Upgrade Clock